Articles from Segal Trials

Segal Trials announced its participation as a clinical research site in the pivotal studies that supported the U.S. Food and Drug Administration’s (FDA) approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. This milestone, announced by Tonix Pharmaceuticals, marks the first new FDA-approved therapy for fibromyalgia in more than 16 years.

Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluating CD388—a novel, non-vaccine, long-acting antiviral—for the prevention of seasonal influenza. Dr. Steven Chavoustie served as the Principal Investigator for the study at Segal Trials.

Segal Trials, a South Florida-based clinical research network specializing in psychiatric and neurological disorders, is proud to recognize the contributions of Dr. Olga Lapeyra to the successful Satsuma Pharmaceuticals Phase 3 clinical trial evaluating Atzumi™ (dihydroergotamine nasal powder), recently approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura in adults.

Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, has released enrollment performance metrics from their participation in NOVA - a Phase 2 dose finding trial in adult patients with acute schizophrenia evaluating LB-102, a once-daily orally administered small molecule and potential first-in-class benzamide antipsychotic.

Segal Trials is honored to have contributed significantly to the FDA approval of COBENFY™ (xanomeline and trospium chloride), a groundbreaking first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults. This approval marks a critical advancement in schizophrenia care, offering new hope to those living with the condition.

Segal Trials is proud to announce its participation in the Latina Expo 2024, hosted by the Center for Information and Study on Clinical Research Participation (CISCRP). Segal Trials, a leading clinical research site network, will be represented by a distinguished panel comprising Tabatha Cirgenski, Director of Marketing, Danielle Recasens, Director of Recruitment, and Amanda Rodriguez, a previous study participant at Segal Trials among other industry Latinas.

Segal Trials, a pioneering clinical research site network, is proud to announce its participation in this year’s CNS Summit that occurred in Boston, MA on November 8-11, 2023, a one of a kind event in the life sciences industry. As a founding member of CNS Summit since 2010, Segal Trials continues to make a significant impact in central nervous system (CNS) research and remains at the forefront of cutting-edge psychedelic science.

Segal Trials, a privately held network of clinical research sites throughout South Florida has concluded a phase 3 EMERGENT-2 trial with Karuna Therapeutics. The study focused on evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia. The study was overseen by Segal Trials, Chief Scientific Officer, & Principal Investigator, Rishi Kakar, MD.